Search studies
11 studies found
PRECISESADS
The goal of this project is to use the power of OMICs, and bioinformatics to identify new classifications for diseases known to share common pathophysiological mechanisms. Such knowledge has not been applied to individual patients, depriving them of potential benefits in terms of the use of new therapeutic agents that are being developed for one disease but cannot be applied in another, due to current clinical classifications. We will investigate individuals with systemic lupus erythematosus ...
1
EPAD
Observational Study. More details available at http://datacat.uni.lu/additional_files/EPAD_Study_Protocol_Description.htm
3
Smart4Health Citizen-Provided data
The purpose of the Smart4Health project is to develop and evaluate the prototype of the Smart4Health platform for the upload and storing of citizens' health-related data, and to offer it as a service. The Smart4Health service providing various features allows to manage and selectively share citizens' data using a web browser on mobile devices or computers. Both development and evaluation of the Smart4Health platform and service are meant to be citizen-centred, thus involving users in order to...
4
APPROACH source cohorts
All baseline cohort parameters, clinical, conventional (knee x-ray and MRI and the robust biochemical markers), and novel markers (T2 relaxation MRI for cartilage collagen distribution, gagCEST MRI cartilage for proteoglycan content, knee CT/x-ray for bone shape and trabecular architecture, knee motion, and novel biochemical markers describing turnover of specific tissue component, as well as involvement of hand, hip and spine joint damage, hand joint inflammation, hip motion and shape and bo...
5
AETIONOMY
Study phase: recruitment. For more details, see http://www.aetionomy.eu/content/dam/scai/AETIONOMY/Dokumente/Aetionomy_Newsletter4_web.pdf
7
OncoTrack
OncoTrack attempts to address the core problems of drug-based cancer therapies: the low response rate of patients to their therapies, as well as its inevitable consequence, the low approval rates of oncology drugs. Only about 10% of cancer drug candidates entering clinical development are granted marketing authorization. Our program is based on two seminal developments: significant progress in our ability to analyze the molecular characteristics of individual tumors and patients (predominantl...
8
